Document:

f8k040208ex10i_fund.htm

    FUND.COM
INC.

     

    INDEMNIFICATION
AGREEMENT

     

    This
Indemnification Agreement (“Agreement”) is made
as of this __ day of March, 2008 by and between Fund.com Inc., a Delaware
corporation (the “Company”), and
______________ (“Indemnitee”).

     

    WHEREAS,
the Company and Indemnitee recognize the significant cost of directors’ and
officers’ liability insurance and the general reductions in the coverage of such
insurance;

     

    WHEREAS,
the Company and Indemnitee further recognize the substantial increase in
corporate litigation in general, subjecting officers and directors to expensive
litigation risks at the same time as the coverage of liability insurance has
been severely limited; and

     

    WHEREAS,
the Company desires to attract and retain the services of highly qualified
individuals, such as Indemnitee, to serve as officers and directors of the
Company and to indemnify its officers and directors so as to provide them with
the maximum protection permitted by law.

     

    NOW,
THEREFORE, in consideration for Indemnitee’s services as an officer or director
of the Company, the Company and Indemnitee hereby agree as follows:

     

    1. Indemnification.

     

    (a) Third Party
Proceedings.  The
Company shall indemnify Indemnitee if Indemnitee is or was a party or is
threatened to be made a party to any threatened, pending or completed action,
suit, proceeding or any alternative dispute resolution mechanism, whether civil,
criminal, administrative or investigative (other than an action by or in the
right of the Company) by reason of the fact that Indemnitee is or was a
director, officer, employee or agent of the Company, or any subsidiary of the
Company, or by reason of the fact that Indemnitee is or was serving at the
request of the Company as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys’ fees), judgments, fines and amounts paid in
settlement (if such settlement is approved in advance by the Company, which
approval shall not be unreasonably withheld) actually and reasonably incurred by
Indemnitee in connection with such action, suit or proceeding if Indemnitee
acted in good faith and in a manner Indemnitee reasonably believed to be in or
not opposed to the best interests of the Company, and, with respect to any
criminal action or proceeding, had no reasonable cause to believe Indemnitee’s
conduct was unlawful.  The termination of any action, suit or
proceeding by judgment, order, settlement, conviction, or upon a plea of nolo
contendere or its equivalent, shall not, of itself, create a presumption that
Indemnitee did not act in good faith and in a manner which Indemnitee reasonably
believed to be in or not opposed to the best interests of the Company, and, with
respect to any criminal action or proceeding, had reasonable cause to believe
that Indemnitee’s conduct was unlawful.

     

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    (b) Proceedings By or in the
Right of the Company.  The
Company shall indemnify Indemnitee if Indemnitee was or is a party or is
threatened to be made a party to any threatened, pending or completed action or
suit by or in the right of the Company or any subsidiary of the Company to
procure a judgment in its favor by reason of the fact that Indemnitee is or was
a director, officer, employee or agent of the Company, or any subsidiary of the
Company, or by reason of the fact that Indemnitee is or was serving at the
request of the Company as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise, against
expenses (including attorneys’ fees) and, to the fullest extent permitted by
law, amounts paid in settlement actually and reasonably incurred by Indemnitee
in connection with the defense or settlement of such action or suit if
Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to
be in or not opposed to the best interests of the Company, except that no
indemnification shall be made in respect of any claim, issue or matter as to
which Indemnitee shall have been adjudged to be liable to the Company unless and
only to the extent that the Court of Chancery of the State of Delaware or the
court in which such action or suit was brought shall determine upon application
that, despite the adjudication of liability but in view of all the circumstances
of the case, Indemnitee is fairly and reasonably entitled to indemnity for such
expenses which the Court of Chancery of the State of Delaware or such other
court shall deem proper.

     

    (c) Mandatory Payment of
Expenses.  To
the extent that Indemnitee has been successful on the merits or otherwise in
defense of any action, suit or proceeding referred to in Subsections (a) and (b)
of this Section 1, or in defense of any claim, issue or matter therein,
Indemnitee shall be indemnified against expenses (including attorneys’ fees)
actually and reasonably incurred by Indemnitee in connection
therewith.

     

    2. Expenses; Indemnification
Procedure.

     

    (a) Advancement of
Expenses.  The
Company shall advance all expenses incurred by Indemnitee in connection with the
investigation, defense, settlement or appeal of any civil or criminal action,
suit or proceeding referenced in Section 1(a) or (b) hereof (but not amounts
actually paid in settlement of any such action, suit or
proceeding).  Indemnitee hereby undertakes to repay such amounts
advanced only if, and to the extent that, it shall ultimately be determined that
Indemnitee is not entitled to be indemnified by the Company as authorized
hereby.  The advances to be made hereunder shall be paid by the
Company to Indemnitee within thirty (30) days following delivery of a written
request therefor by Indemnitee to the Company.

     

    (b) Notice/Cooperation by
Indemnitee.  Indemnitee
shall, as a condition precedent to his right to be indemnified under this
Agreement, give the Company notice in writing as soon as practicable of any
claim made against Indemnitee for which indemnification will or could be sought
under this Agreement.  Notice to the Company shall be directed to the
President of the Company at the address shown on the signature page of this
Agreement (or such other address as the Company shall designate in writing to
Indemnitee).  Notice shall be deemed received three business days
after the date postmarked if sent by domestic certified or registered mail,
properly addressed, five business days if sent by airmail to a country outside
of North America; otherwise notice shall be deemed received when such notice
shall actually be received by the Company.  In addition, Indemnitee
shall give the Company such information and cooperation as it may reasonably
require and as shall be within Indemnitee’s power.

     

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

     

    (c) Procedure.  Any
indemnification and advances provided for in Section 1 and this Section 2 shall
be made no later than thirty (30) days after receipt of the written request of
Indemnitee.  If a claim under this Agreement, under any statute, or
under any provision of the Company’s Certificate of Incorporation or Bylaws
providing for indemnification, is not paid in full by the Company within thirty
(30) days after a written request for payment thereof has first been received by
the Company, Indemnitee may, but need not, at any time thereafter bring an
action against the Company to recover the unpaid amount of the claim and,
subject to Section 12 of this Agreement, Indemnitee shall also be entitled to be
paid for the expenses (including attorneys’ fees) of bringing such
action.  It shall be a defense to any such action (other than an
action brought to enforce a claim for expenses incurred in connection with any
action, suit or proceeding in advance of its final disposition) that Indemnitee
has not met the standards of conduct which make it permissible under applicable
law for the Company to indemnify Indemnitee for the amount
claimed.  However, Indemnitee shall be entitled to receive interim
payments of expenses pursuant to Subsection 2(a) unless and until such defense
may be finally adjudicated by court order or judgment from which no further
right of appeal exists.  It is the parties’ intention that if the
Company contests Indemnitee’s right to indemnification, the question of
Indemnitee’s right to indemnification shall be for the court to decide, and
neither the failure of the Company (including its Board of Directors, any
committee or subgroup of the Board of Directors, independent legal counsel, or
its stockholders) to have made a determination that indemnification of
Indemnitee is proper in the circumstances because Indemnitee has met the
applicable standard of conduct required by applicable law, nor an actual
determination by the Company (including it Board of Directors, any committee or
subgroup of the Board of Directors, independent legal counsel, or its
stockholders) that Indemnitee has not met such applicable standard of conduct,
shall create a presumption that Indemnitee has or has not met the applicable
standard of conduct.

     

    (d) Notice to
Insurers.  If,
at the time of the receipt of a notice of a claim pursuant to Section 2(b)
hereof, the Company has director and officer liability insurance in effect, the
Company shall give prompt notice of the commencement of such proceeding to the
insurers in accordance with the procedures set forth in the respective
policies.  The Company shall thereafter take all necessary or
desirable action to cause such insurers to pay, on behalf of the Indemnitee, all
amounts payable as a result of such proceeding in accordance with the terms of
such policies.

     

    (e) Selection of
Counsel.  In
the event the Company shall be obligated under Section 2(a) hereof to pay the
expenses of any proceeding against Indemnitee, the Company, if appropriate,
shall be entitled to assume the defense of such proceeding, with counsel
approved by Indemnitee, upon the delivery to Indemnitee of written notice of its
election to do so.  After delivery of such notice, approval of such
counsel by Indemnitee and the retention of such counsel by the Company, the
Company will not be liable to Indemnitee under this Agreement for any fees of
counsel subsequently incurred by Indemnitee with respect to the same proceeding,
provided, that (i)
Indemnitee shall have the right to employ his counsel in any such proceeding at
Indemnitee’s expense; and (ii) if (A) the employment of counsel by Indemnitee
has been previously authorized by the Company, (B) Indemnitee shall have
reasonably concluded that there may be a conflict of interest between the
Company and Indemnitee in the conduct of any such defense, or (C) the Company
shall not, in fact, have employed counsel to assume the defense of such
proceeding, then the fees and expenses of Indemnitee’s counsel shall be at the
expense of the Company.

     

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

     

     

     

    3. Additional Indemnification
Rights; Nonexclusivity.

     

    (a) Scope.  Notwithstanding
any other provision of this Agreement, the Company hereby agrees to indemnify
the Indemnitee to the fullest extent permitted by law, notwithstanding that such
indemnification is not specifically authorized by the other provisions of this
Agreement, the Company’s Certificate of Incorporation, the Company’s Bylaws or
by statute.  In the event of any change, after the date of this
Agreement, in any applicable law, statute, or rule which expands the right of a
Delaware corporation to indemnify a member of its board of directors or an
officer, such changes shall be, ipso facto, within the purview of Indemnitee’s
rights and Company’s obligations, under this Agreement.  In the event
of any change in any applicable law, statute or rule which narrows the right of
a Delaware corporation to indemnify a member of its board of directors or an
officer, such changes, to the extent not otherwise required by such law, statute
or rule to be applied to this Agreement shall have no effect on this Agreement
or the parties’ rights and obligations hereunder.

     

    (b) Nonexclusivity.  The
indemnification provided by this Agreement shall not be deemed exclusive of any
rights to which Indemnitee may be entitled under the Company’s Certificate of
Incorporation, its Bylaws, any agreement, any vote of stockholders or
disinterested Directors, the General Corporation Law of the State of Delaware,
or otherwise, both as to action in Indemnitee’s official capacity and as to
action in another capacity while holding such office.  The
indemnification provided under this Agreement shall continue as to Indemnitee
for any action taken or not taken while serving in an indemnified capacity even
though he may have ceased to serve in such capacity at the time of any action,
suit or other covered proceeding.

     

    4. Partial
Indemnification.  If
Indemnitee is entitled under any provision of this Agreement to indemnification
by the Company for some or a portion of the expenses, judgments, fines or
penalties actually or reasonably incurred by him in the investigation, defense,
appeal or settlement of any civil or criminal action, suit or proceeding, but
not, however, for the total amount thereof, the Company shall nevertheless
indemnify Indemnitee for the portion of such expenses, judgments, fines or
penalties to which Indemnitee is entitled.

     

    5. Mutual
Acknowledgement.  Both
the Company and Indemnitee acknowledge that in certain instances, Federal law or
applicable public policy may prohibit the Company from indemnifying its
directors and officers under this Agreement or otherwise.  Indemnitee
understands and acknowledges that the Company has undertaken or may be required
in the future to undertake with the Securities and Exchange Commission to submit
the question of indemnification to a court in certain circumstances for a
determination of the Company’s right under public policy to indemnify
Indemnitee.

     

     

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

     

    6. Officer and Director
Liability Insurance.  The
Company shall, from time to time, make the good faith determination whether or
not it is practicable for the Company to obtain and maintain a policy or
policies of insurance with reputable insurance companies providing the officers
and directors of the Company with coverage for losses from wrongful acts, or to
ensure the Company’s performance of its indemnification obligations under this
Agreement.  Among other considerations, the Company will weigh the
costs of obtaining such insurance coverage against the protection afforded by
such coverage.  In all policies of director and officer liability
insurance, Indemnitee shall be named as an insured in such a manner as to
provide Indemnitee the same rights and benefits as are accorded to the most
favorably insured of the Company’s directors, if Indemnitee is a director; or of
the Company’s officers, if Indemnitee is not a director of the Company but is an
officer.  Notwithstanding the foregoing, the Company shall have no
obligation to obtain or maintain such insurance if the Company determines in
good faith that such insurance is not reasonably available, if the premium costs
for such insurance are disproportionate to the amount of coverage provided, if
the coverage provided by such insurance is limited by exclusions so as to
provide an insufficient benefit, or if Indemnitee is covered by similar
insurance maintained by a subsidiary or parent of the Company.

     

    7. Severability.  Nothing
in this Agreement is intended to require or shall be construed as requiring the
Company to do or fail to do any act in violation of applicable
law.  The Company’s inability, pursuant to court order, to perform its
obligations under this Agreement shall not constitute a breach of this
Agreement.  The provisions of this Agreement shall be severable as
provided in this Section 7.  If this Agreement or any portion hereof
shall be invalidated on any ground by any court of competent jurisdiction, then
the Company shall nevertheless indemnify Indemnitee to the full extent permitted
by any applicable portion of this Agreement that shall not have been
invalidated, and the balance of this Agreement not so invalidated shall be
enforceable in accordance with its terms.

     

    8. Exceptions.  Any
other provision herein to the contrary notwithstanding, the Company shall not be
obligated pursuant to the terms of this Agreement:

     

    (a) Claims Initiated by
Indemnitee.  To
indemnify or advance expenses to Indemnitee with respect to proceedings or
claims initiated or brought voluntarily by Indemnitee and not by way of defense,
except with respect to proceedings brought to establish or enforce a right to
indemnification under this Agreement or any other statute or law or otherwise as
required under Section 145 of the Delaware General Corporation Law, but such
indemnification or advancement of expenses may be provided by the Company in
specific cases if the Board of Directors has approved the initiation or bringing
of such suit;

     

    (b) Lack of Good
Faith.  To
indemnify Indemnitee for any expenses incurred by the Indemnitee with respect to
any proceeding instituted by Indemnitee to enforce or interpret this Agreement,
if a court of competent jurisdiction determines that each of the material
assertions made by the Indemnitee in such proceeding was not made in good faith
or was frivolous;

     

    (c) Insured
Claims.  To
indemnify Indemnitee for expenses or liabilities of any type whatsoever
(including, but not limited to, judgments, fines, ERISA excise taxes or
penalties, and amounts paid in settlement) which have been paid directly to
Indemnitee by an insurance carrier under a policy of officers’ and directors’
liability insurance maintained by the Company; or

     

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

     

     

    (d) Claims Under Section
16(b).  To
indemnify Indemnitee for expenses and the payment of profits arising from the
purchase and sale by Indemnitee of securities in violation of Section 16(b) of
the Securities Exchange Act of 1934, as amended, or any similar successor
statute.

     

    9. Construction of Certain
Phrases.

     

    (a) For
purposes of this Agreement, references to the “Company” shall
include, in addition to the resulting corporation, any constituent corporation
(including any constituent of a constituent) absorbed in a consolidation or
merger which, if its separate existence had continued, would have had power and
authority to indemnify its directors, officers, and employees or agents, so that
if Indemnitee is or was a director, officer, employee or agent of such
constituent corporation, or is or was serving at the request of such constituent
corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, Indemnitee shall stand in
the same position under the provisions of this Agreement with respect to the
resulting or surviving corporation as Indemnitee would have with respect to such
constituent corporation if its separate existence had continued.

     

    (b) For
purposes of this Agreement, references to “other enterprises” shall include
employee benefit plans; references to “fines” shall include any excise taxes
assessed on Indemnitee with respect to an employee benefit plan; and references
to “serving at the request of the Company” shall include any service as a
director, officer, employee or agent of the Company which imposes duties on, or
involves services by, such director, officer, employee or agent with respect to
an employee benefit plan, its participants, or beneficiaries; and if Indemnitee
acted in good faith and in a manner Indemnitee reasonably believed to be in the
interest of the participants and beneficiaries of an employee benefit plan,
Indemnitee shall be deemed to have acted in a manner “not opposed to the best
interests of the Company” as referred to in this Agreement.

     

    10. Counterparts.  This
Agreement may be executed in one or more counterparts, each of which shall
constitute an original.

     

    11. Successors and
Assigns.  This
Agreement shall be binding upon the Company and its successors and assigns, and
shall inure to the benefit of Indemnitee and Indemnitee’s estate, heirs, legal
representatives and assigns.

     

    12. Attorneys’
Fees.  In
the event that any action is instituted by Indemnitee under this Agreement to
enforce or interpret any of the terms hereof, Indemnitee shall be entitled to be
paid all court costs and expenses, including reasonable attorneys’ fees,
incurred by Indemnitee with respect to such action, unless as a part of such
action, the court of competent jurisdiction determines that each of the material
assertions made by Indemnitee as a basis for such action were not made in good
faith or were frivolous.  In the event of an action instituted by or
in the name of the Company under this Agreement or to enforce or interpret any
of the terms of this Agreement, Indemnitee shall be entitled to be paid all
court costs and expenses, including attorneys’ fees, incurred by Indemnitee in
defense of such action (including with respect to Indemnitee’s counterclaims and
cross-claims made in such action), unless as a part of such action the court
determines that each of Indemnitee’s material defenses to such action were made
in bad faith or were frivolous.

     

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

     

     

    13. Notice.  All
notices, requests, demands and other communications under this Agreement shall
be in writing and shall be deemed duly given (i) if delivered by hand and
receipted for by the party addressee, on the date of such receipt, or (ii) if
mailed by domestic certified or registered mail with postage prepaid, on the
third business day after the date postmarked.  Addresses for notice to
either party are as shown on the signature page of this Agreement, or as
subsequently modified by written notice.

     

    14. Consent to
Jurisdiction.  The
Company and Indemnitee each hereby irrevocably consent to the jurisdiction of
the courts of the State of New York for all purposes in connection with any
action or proceeding which arises out of or relates to this Agreement and agree
that any action instituted under this Agreement shall be brought only in the
state courts of the State of New York.

     

    15. Choice of
Law.  This
Agreement shall be governed by and its provisions construed in accordance with
the laws of the State of New York, as applied to contracts between New York
residents entered into and to be performed entirely within New York without
regard to the conflict of law principles thereof.

     

    16. Period of
Limitations.  No
legal action shall be brought and no cause of action shall be asserted by or in
the right of the Company against Indemnitee, Indemnitee’s estate, spouse, heirs,
executors or personal or legal representatives after the expiration of two years
from the date of accrual of such cause of action, and any claim or cause of
action of the Company shall be extinguished and deemed released unless asserted
by the timely filing of a legal action within such two-year period; provided, however, that if
any shorter period of limitations is otherwise applicable to any such cause of
action, such shorter period shall govern.

     

    17. Subrogation.  In
the event of payment under this Agreement, the Company shall be subrogated to
the extent of such payment to all of the rights of recovery of Indemnitee, who
shall execute all documents required and shall do all acts that may be necessary
to secure such rights and to enable the Company effectively to bring suit to
enforce such rights.

     

    18. Amendment and
Termination.  No
amendment, modification, termination or cancellation of this Agreement shall be
effective unless it is in writing signed by both the parties
hereto.  No waiver of any of the provisions of this Agreement shall be
deemed or shall constitute a waiver of any other provisions hereof (whether or
not similar) nor shall such waiver constitute a continuing waiver.

     

    19. Integration and Entire
Agreement.  This
Agreement sets forth the entire understanding between the parties hereto and
supersedes and merges all previous written and oral negotiations, commitments,
understandings and agreements relating to the subject matter hereof between the
parties hereto.

     

    [Signature
page to follow]

     

     

     

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

     

     

    IN
WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date
first above written.

     

    FUND.COM
INC.

    

    

    By:
_____________________________________

    Name:  Raymond
Lang

    
      Title:   
Chief
Executive Officer

    

    
    

    

    Address:       
______________________________

            ______________________________

            ______________________________

     

    

    

    AGREED
TO AND ACCEPTED:

    

    INDEMNITEE:

    

    

    By:
_________________________________

    Name:

    

    

    Address:       
______________________________

            ______________________________

            ______________________________EX-10.66

Exhibit 10.66

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 24b-2 OF THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

Confidential

CYTOKINETICS, INC.

SCIENTIFIC ADVISORY BOARD

CONSULTING AGREEMENT

This Consulting Agreement (the “Agreement”) is made and effective as of April 1, 2008
(the “Effective Date”), by and between Cytokinetics, Inc. (the “Company”) and James
H. Sabry, M.D., Ph.D., an individual (“Consultant”).

WHEREAS, the Company wishes to retain the services of Consultant from time to time to obtain
advice regarding the Field of Interest (as defined below); and

WHEREAS, Consultant wishes to provide such services to the Company in accordance with the
terms and conditions of this Agreement;

NOW, THEREFORE, in consideration of the premises and mutual promises set forth in this
Agreement, and other good and valuable consideration, the exchange, receipt and sufficiency of
which are acknowledged, the parties hereby agree as follows:

1. Services.

1.1 The Company hereby retains Consultant as a consultant and advisor to the Company.
Consultant’s consultation will involve the specialized field of pharmaceutical research and
development and related business and corporate development activities (the “Field of
Interest”) and requires the application of the unique, special and extraordinary skills and
knowledge that Consultant possesses in the Field of Interest.

1.2 Consultant hereby agrees to perform the following services for the Company under this
Agreement (the “Services”), as requested by the Company:

(i) Chair the Company’s Scientific Advisory Board and attend formal meetings with Company’s
scientists or management or as otherwise designated by Company;

(ii) Mentoring of the Company’s staff as assigned;

(iii) During the months of April-June 2008 support smooth transition and
implementation of the R&D strategic planning initiative:

(iii) Advise the Company’s management, employees and agents, at reasonable times, in matters
related to the Field of Interest; and

(iv) Provide such other consultation or advisory services as may be requested by the Company.

1.3 Consultant will provide the Services over the telephone or through written or electronic
correspondence as requested by the Company, and will make himself available in person at the
Company’s offices or other locations at mutually agreeable times. From the Effective Date through
June 30, 2008, the parties anticipate that Consultant will provide twelve

Page 1 of 10

(12) days of consulting per month. Thereafter, parties anticipate that Consultant will
provide two (2) days of consulting per month.

1.4 Consultant hereby represents and warrants that he or she will perform the Services using
at all times his best professional knowledge, ability, skill, judgment and efforts, in a
workman-like manner, and in accordance with the highest standards of competence, diligence and
performance.

2. Expenses. The Company will reimburse Consultant’s reasonable, documented expenses
incurred at the Company’s request in connection with the Services (including travel expenses, which
will be reimbursed in accordance with the Company’s standard travel policy), subject to customary
verification in a form reasonably acceptable to the Company. Invoices for expenses and
accompanying documentation must be submitted within thirty (30) days of the end of the month in
which such expenses were incurred. The Company will pay correct invoices within thirty (30) days
of receipt.

3. Compensation. From the Effective Date through June 30, 2008, Consultant will
receive a monthly fee of thirty thousand dollars ($30,000). Thereafter, Consultant will receive a
monthly fee of five thousand dollars ($5,000). Such fees will be paid in arrears within thirty
(30) days from the end of each month during the term of this Agreement, pro-rated for partial
months. Travel time is not compensable. The compensation paid under this Section 3 will be deemed
full compensation for Consultant’s performance of the Services and all other obligations undertaken
by Consultant hereunder.

4. Term and Termination. This Agreement will take effect as of the Effective Date and
continue for an initial term expiring December 31, 2008, and will then automatically renew for
successive one-year terms. Either party may terminate this Agreement at any time, with or without
cause, upon sixty (60) days prior written notice to the other party. The obligations of Sections
4, 5, 6.2, 7, 8, 9, 11, 12 and 13 hereof will survive expiration or any termination of this
Agreement. Expiration or termination of this Agreement will not relieve either party of any
liability or obligation which accrued hereunder prior to the effective date of such termination,
nor preclude either party from pursuing all rights and remedies it may have hereunder or at law or
in equity with respect to any breach of this Agreement, nor prejudice either party’s right to
obtain performance of any obligation.

5. Inventions.

5.1 Consultant will promptly disclose in writing to the Company’s President, or to any other
persons designated by the Company, all “Company Inventions.” As used herein, “Company
Inventions” means all improvements, inventions, designs, formulas, compounds, structures, works
of authorship, trade secrets, technology, computer programs, ideas, processes, techniques,
know-how, data and information, whether or not patentable or copyrightable, which Consultant,
either alone or jointly, makes, discovers, conceives of and/or reduces to practice in the course of
or as a result of performing Services, or through use of any Confidential Information (as defined
below). Consultant will not disclose Company Inventions to any person outside the Company unless
the Company so requests in writing.

Page 2 of 10

5.2 All Company Inventions and all title, patents, patent rights, copyrights, mask work
rights, trade secret rights and other intellectual property and rights anywhere in the world in
connection therewith (collectively “Rights”) will be the Company’s sole and exclusive
property. Consultant hereby assigns, and automatically will be deemed to have assigned, to the
Company all Rights in and to all Company Inventions.

5.3 Consultant agrees to perform, during and after the term of this Agreement, all acts the
Company reasonably deems necessary or desirable to permit and assist it in evidencing, perfecting,
obtaining, maintaining, defending and enforcing its Rights in the Company Inventions and/or
Consultant’s assignment with respect thereto in any and all countries. Such acts may include, but
are not limited to, execution of documents and assistance in legal proceedings. If for any reason
whatsoever the Company is unable to secure Consultant’s signature on any document needed in
connection with furthering the purposes of this Section 5.3, Consultant hereby irrevocably
designates and appoints the Company and its duly authorized officers and agents as Consultant’s
agents and attorneys-in-fact, to act for and in behalf and instead of Consultant, to execute and
file any documents and to do all other lawfully permitted acts to further the purposes of this
Section 5.3 with the same legal force and effect as if executed by Consultant.

5.4 Any assignment of copyright hereunder includes all rights of paternity, integrity,
disclosure and withdrawal and any other rights that may be known as or referred to as “moral
rights” (collectively “Moral Rights”). To the extent such Moral Rights cannot be assigned
under applicable law and to the extent the following is allowed by the laws in various countries
where Moral Rights exist, Consultant hereby waives such Moral Rights and consents to any action of
the Company that would violate such Moral Rights in the absence of such consent. Consultant will
confirm any such waivers and consents as requested by the Company.

6. Third Party Agreements; Segregation of Services.

6.1 Subject to written waivers that the Company may provide upon request and which it will not
unreasonably withhold, Consultant will not directly or indirectly, during the term of this
Agreement: (i) provide any services in the Excluded Field (as defined below) to any other business
or commercial entity, (ii) provide any services for any company that is competitive with the
Company, or (iii) participate in the formation of any business or commercial entity in the Field of
Interest or otherwise competitive with the Company. Consultant will list in Exhibit A
attached hereto all other companies for which Consultant is providing services (“Outside
Companies”) as of the Effective Date, and will promptly update such list as new engagements
arise during the term of this Agreement. As used herein, “Excluded Field” means activities
(including, without limitation, pharmacology and clinical applications) relating to: (a) [***] (b)
[***]; (c) [***]; (d) [***]; or (e) any other current (as of the Effective Date) or future
molecular target, biology or pathway that is the subject of a Company research or development
program, provided that if Consultant is unable to commit to exclusivity with respect to any future
molecular target, biology or pathway he will promptly inform the Company and the parties will agree
upon an appropriate resolution (which may include Consultant’s recusal from discussions relating to
such molecular target, biology or pathway).

Page 3 of 10

*** Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

6.2 Consultant will not perform the Services on time that is required to be devoted to
any third party. Consultant will not use the funding, resources, materials, personnel or
facilities of any third party to perform the Services without the Company’s prior written consent,
and will not perform the Services in any manner that would give any third party rights or access to
any products of the Services. Without limiting the generality of the foregoing, Consultant will:
(i) segregate the Services from Consultant’s work performed for any third party so as to minimize
any questions of disclosure of, or rights under, any intellectual property; (ii) immediately notify
the Company in writing if at any time Consultant believes that such questions may result from his
or her performance under this Agreement; and (iii) assist the Company in fairly resolving any
questions in this regard which may arise. Consultant represents and warrants that he or she has
disclosed and immediately will disclose to the Company any conflicts between this Agreement and any
other agreements binding Consultant.

6.3 Consultant will not disclose to the Company any information that Consultant is obligated
to keep secret pursuant to a confidentiality agreement with a third party, and nothing in this
Agreement will impose any obligation on Consultant to the contrary.

6.4 During the term of this Agreement, subject to Consultant’s confidentiality obligations to
third parties, Consultant will disclose to the Company’s President, on a confidential basis,
technology and product opportunities which come to Consultant’s attention in the Excluded Field,
and any invention, improvement, discovery, process, formula or method or other intellectual
property relating to or useful in, the Excluded Field, whether or not patentable or copyrightable,
and whether or not discovered or developed by Consultant.

7. Non-Solicitation. During the term of this Agreement and for a period of twelve
(12) months thereafter, Consultant will not, directly or indirectly, solicit, hire away, or induce
to leave any employee or consultant of the Company.

8. Confidentiality.

8.1 As used herein, “Confidential Information” means: (i) any information disclosed to
Consultant by or on behalf of the Company, either directly or indirectly, in writing, graphically,
electronically, orally or by inspection, including, without limitation, information comprising or
relating to any: (a) compound, extract, media, vector, gene, protein, sequence, cell, cell line,
formulation, sample or other composition, including, without limitation, any structural information
or methods of synthesis relating to any of the foregoing; (b) assay, procedure, algorithm, software
program, discovery, invention, model, formula, data, result, idea or technique; (c) trade secret,
trade dress, copyright, patent or other intellectual property right or any registration or
application therefor or materials relating thereto; or (d) research, development, purchasing,
manufacturing, engineering, marketing, servicing, sales, financing, legal or other business or
corporate financial activities and/or present or future products, design details or specifications,
prices, plans, forecasts, suppliers, clients, customers, employees, consultants or investors; (ii)
all information developed by or for Consultant pursuant to the Services, including, without
limitation, all Company Inventions; (iii) any information which the Company has received from a
third party which the Company is obligated to treat as confidential or proprietary; and (iv) the
terms, existence and subject matter of this Agreement. Consultant

Page 4 of 10

acknowledges that the Company’s business is extremely competitive, dependent upon the
maintenance of secrecy and any disclosure of any Confidential Information would result in serious
harm to the Company.

8.2 Consultant will use the Confidential Information only as necessary for the Services, and
will not use any Confidential Information in any way detrimental to the Company.

8.3 Consultant will:

(i) hold the Confidential Information and any information derived therefrom in strictest
confidence and protect such Confidential Information (including, without limitation, taking at
least that level of care Consultant employs with respect to his or her most sensitive confidential
materials, but in any event a reasonable level of care);

(ii) maintain all Confidential Information and any information derived therefrom wholly
separate from information provided to Consultant by or belonging to any third party;

(iii) not take any Confidential Information or any information derived therefrom into the
facilities of any third party;

(iv) not, directly or indirectly, disclose, transfer or otherwise make available any
Confidential Information or any information derived therefrom to any third person; and

(v) not copy or reverse engineer any Confidential Information.

8.4 The term “Confidential Information” does not include any information that Consultant can
show by competent, written proof:

(i) is or becomes generally known to the public through no improper action or inaction by
Consultant;

(ii) was in Consultant’s possession or known to Consultant prior to receipt from the Company;
or

(iii) was rightfully disclosed to Consultant by a third party without restriction on further
disclosure.

Notwithstanding the foregoing, all Company Inventions will remain at all times Confidential
Information.

8.5 Consultant may disclose any Confidential Information that is duly required to be disclosed
by law, government regulation or court order. If such disclosure is required, Consultant will give
the Company at least 30 days advance written notice, or such advance written notice as is
reasonably practicable under the circumstances, to enable the Company to seek confidential
treatment of such Confidential Information, whether by protective order or otherwise, and
Consultant will cooperate fully with the Company in such efforts.

Page 5 of 10

8.6 Consultant will notify the Company in writing immediately upon becoming aware of any
unauthorized release or other breach of this Section 8.

8.7 Upon the earlier of expiration or termination of this Agreement, or upon the Company’s
request, Consultant will promptly return to the Company all materials containing Confidential
Information as well as data, records, reports, notes, compilations and other property, whether or
not pertaining to Confidential Information, furnished by the Company to Consultant or produced by
Consultant in connection with the Services rendered hereunder, together with all copies of any of
the foregoing.

8.8 Consultant is not granted any rights under any of the Company’s patent rights, copyrights
or other property rights, nor will this Agreement grant Consultant any rights in or to any
Confidential Information, except for the purpose of providing Services to the Company.

9. Use of Name. Consultant’s name may appear on the Company’s website as a member of
the Company’s scientific advisory board and in certain Company disclosure documents, including,
without limitation: (i) those provided to investors, potential investors, advisors, partners and
affiliates of the Company; and (ii) those required by securities laws and in other regulatory and
administrative filings in the ordinary course of the Company’s business. Consultant will not use
the Company’s name without the Company’s prior written consent.

10. No Conflict: Valid and Binding. Each party represents and warrants that neither
the execution of this Agreement nor the performance of its obligations under this Agreement will
result in a violation or breach of any other agreement by which such party is bound, and that this
Agreement is valid and legally binding in accordance with its terms.

11. Compliance with Company Policies. Consultant agrees to fully comply with all of
the Company’s then-current policies and procedures, including, without limitation, the Company’s
Insider Trading Compliance Program.

12. Anti-Harassment Policy. The Company is committed to providing a work environment
free of discrimination and harassment, and discrimination or harassment of any kind is strictly
prohibited. Contractor’s engaging in unlawful sexual harassment, other harassment or
discrimination on any protected bases may result in the immediate termination of this Agreement.

13. Miscellaneous.

13.1 No Debarment.

(i) Consultant hereby represents and warrants that:

(a) He or she has not been debarred under the Generic Drug Enforcement Act or any similar law
or regulation; and

(b) He or she has not been indicted for or convicted of a felony under any applicable law or
regulation for conduct: (1) relating to the development or approval, including the process for
development or approval, of any drug, product or medical device; or (2)

Page 6 of 10

otherwise relating to the regulation of any drug product or medical device under the FD&C Act
or any similar law.

(ii) Consultant will immediately inform the Company in writing of any debarment, or the
commencement of any debarment or like proceedings against Consultant during the term of this
Agreement. In such event, the Company may terminate this Agreement effective upon Consultant’s
receipt of written notice thereof.

13.2 Notices. Any notice provided under this Agreement will be in writing and will be
deemed to have been effectively given (i) upon receipt when delivered personally, (ii) one day
after sending when sent by private express mail service (such as Federal Express), or (iii) 3 days
after sending when sent by regular mail to the following address:

In the case of the Company:

Cytokinetics, Inc.

280 East Grand Avenue

South San Francisco, CA 94080

Attn: President and CEO

In the case of Consultant:

James H. Sabry, M.D., Ph.D.

[***]

[***]

or to other such address as may have been designated by the Company or Consultant by notice to the
other given as provided herein.

13.3 Independent Contractor: Withholding. Consultant will at all times be an
independent contractor, and as such will not have authority to bind the Company. Consultant will
not enter into any agreements or incur any obligations on the Company’s behalf. Consultant will
not act as an agent nor be deemed to be an employee of the Company for the purposes of any employee
benefit program, unemployment benefits, or otherwise. The Company will not withhold any amounts
from Consultant’s compensation for payment of any federal, state, or local taxes, and Consultant
has sole responsibility to pay such taxes, if any, and file such returns as will be required by
applicable laws and regulations. To the extent required by laws and regulations of the State of
California and the U.S. Government, the Company will report such compensation to the appropriate
state and federal regulatory agencies. Consultant hereby indemnifies the Company against any
obligation imposed on the Company to pay withholding taxes or similar items or resulting from a
court’s or governmental entity’s determination that Consultant is not an independent contractor to
the Company.

13.4 Assignment. Due to the personal nature of the Services to be rendered by
Consultant, Consultant may not assign this Agreement. The Company may assign all rights and
liabilities under this Agreement to a subsidiary or an affiliate or to a successor to all or a
substantial part of its business and assets without Consultant’s consent. Subject to the
foregoing,

Page 7 of 10

*** Certain information on this page has been omitted and filed separately with the
Commission. Confidential treatment has been requested with respect to the omitted portions.

this Agreement will inure to the benefit of and be binding upon each of the heirs, assigns and
successors of the respective parties. Any purported assignment that does not comport with this
Section will be null, void and of no effect.

13.5 Severability. If any provision of this Agreement is declared invalid, illegal or
unenforceable by a court of competent jurisdiction, such provision will be severed and the
remaining provisions will continue in full force and effect.

13.6 Remedies. The remedies provided hereunder are cumulative, and are not exclusive
of other remedies available to either party in law or equity. Consultant hereby acknowledges and
agrees that in the event of Consultant’s actual or threatened breach of this Agreement relating to
confidentiality and/or intellectual property, including, without limitation, the actual or
threatened disclosure of Confidential Information without the Company’s prior express written
consent, the Company will suffer an irreparable and continuing injury such that no remedy at law
will afford it adequate protection against, or appropriate compensation for, such injury.
Accordingly, Consultant hereby agrees that, in such event, and in addition to any other remedies
that may be available in law, in equity or otherwise, the Company will be entitled to obtain
injunctive relief against such breach or threatened breach of this Agreement without the necessity
of proving actual damages or posting bond.

13.7 Governing Law; Dispute Resolution. This Agreement will be governed and construed
in accordance with the laws of the State of California as applied to transactions taking place
wholly within California between California residents. For any legal action arising from or
related to this Agreement, the parties hereby irrevocably: (i) consent and submit solely to
jurisdiction and venue of the state and federal courts located in San Francisco County, California;
(ii) agree that such courts will be the sole courts utilized; and (iii) waive any jurisdictional or
venue objections to such courts, including, without limitation, forum non conveniens. The
prevailing party in any action to enforce this Agreement will be entitled to costs and attorneys’
fees. No provision of this Agreement will be strictly construed against either party, irrespective
of which party is deemed to have authored such provision.

13.8 Entire Agreement; Amendment. This Agreement represents the entire understanding
of the parties relating to the subject matter hereof and supersedes all prior agreements between
the parties relating to such subject matter. This Agreement may only be amended in writing
executed by the Company and Consultant. For clarity, this Agreement is not intended to supersede
or modify Consultant’s fiduciary obligations as a member of the Company’s Board of Directors.

13.9 Indemnification. Consultant will indemnify and hold the Company and its
directors, officers, employees and agents harmless from and against any and all damages, costs,
expenses, losses and other liabilities, including, without limitation, reasonable attorney’s fees
and court costs, incurred in connection with any claim, action or proceeding arising in connection
with Consultant’s negligence, intentional misconduct or breach of any obligation, representation or
warranty hereunder.

Page 8 of 10

13.10 Headings. The headings for each Article and Section in this Agreement have
been inserted for convenience of reference only and are not intended to limit or expand on the
meaning of the language contained in the particular Article or Section.

13.11 Waiver. Waiver or forbearance by either party or the failure by either party to
claim a breach of any provision of this Agreement or exercise any right or remedy provided by this
Agreement or applicable law will not be deemed to constitute a waiver with respect to any
subsequent breach of any provision hereof, excepting only as to an express written and signed
waiver as to a particular matter for a particular period of time.

13.12 Further Actions. Consultant agrees to execute, acknowledge and deliver such
further instruments, and to do all such other acts, as may be necessary or appropriate in order to
carry out the purposes and intent of this Agreement.

13.13 Counterparts. This Agreement may be executed in two or more counterparts, each
of which will be deemed an original and all of which will together be deemed to constitute one
agreement

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

	 	 	 
	CYTOKINETICS, INC.

By:

	 	CONSULTANT

By:
	/s/ Robert I. Blum

	 	/s/ James H. Sabry
	 

	 	 
	Print Name: Robert I. Blum

	 	Print Name: James H. Sabry, M.D., Ph.D.
	 

	 	 
	Title: President and CEO

	 	Taxpayer I.D. Number:
	 

	 	 
	Date:

	 	Date:
	3/27/08

	 	3/31/08
	 

	 	 

Page 9 of 10

1

EXHIBIT A

OUTSIDE COMPANIES

Arete Therapeutics, Inc.

Prospect Venture Partners

Hopelab

Page 10 of 10

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00140-of-00352.parquet"}]]